GLP-1 Side Effects Get Real: What New Data Says About ENT Symptoms and Colonoscopy Prep
Two fresh analyses push the GLP-1 conversation past nausea, flagging ear-nose-throat signals and a higher risk of failed bowel prep. Here's what tired parents juggling a new prescription actually need to know.
If you started a GLP-1 medication sometime between the 3 a.m. feeds and the school run, you probably braced for the famous side effects: the queasy first weeks, the smaller appetite, the food noise dialing down. What you may not have been warned about is quieter and weirder — a metallic taste that won't quit, a hoarse voice, or a colonoscopy prep that, despite your best efforts, simply doesn't work. Two new analyses published this year sharpen the picture of what these drugs do beyond the stomach, and they're worth a calm read before your next refill.
GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide — have moved fast from diabetes clinics into mainstream weight care. Most of what parents hear about side effects still centers on nausea and constipation. But as prescriptions multiply, researchers are mining adverse-event databases and pooling trial data to catch the less-discussed signals. The two studies driving this piece are not the final word; they're a moderate-strength nudge to ask better questions at your next appointment.
What the ENT signal actually says
The first analysis, published in The Laryngoscope, combed through the FDA's Adverse Event Reporting System (FAERS) for ear, nose and throat complaints tied to the five major GLP-1 drugs, from one year after each approval through the end of 2023. Across 9,746 reported adverse events, the standouts were not subtle: medullary and papillary thyroid carcinoma signals showed up across virtually all of the drugs, echoing a known boxed-warning concern, and reflux (GERD) was significant for every agent assessed.
The genuinely new texture is in the head-and-neck signals. Semaglutide — the molecule in Ozempic and Wegovy — flagged statistically for anosmia (loss of smell), dry mouth, dysgeusia (altered taste) and Bell's palsy. Liraglutide flagged for dysphonia (voice changes), dysgeusia, tinnitus and Bell's palsy. Exenatide showed signals including dysgeusia and hearing disability. None of this proves the drug caused the symptom in any given person — FAERS is a reporting system, not a controlled trial, and people on these medications are also losing weight, changing diets and aging in real time. But a signal strong enough to clear the authors' thresholds is a signal worth naming.
Dry mouth and altered taste were among the head-and-neck signals flagged in the FAERS review — small annoyances that can quietly affect hydration and appetite.
Why your colonoscopy prep may not be working
The second study, a systematic review and meta-analysis in The American Journal of Gastroenterology, asked a very practical question: do GLP-1 drugs make colonoscopy prep harder? Pooling five studies and 10,833 patients (about half on GLP-1s, half not), the authors found the GLP-1 group had roughly twice the odds of inadequate bowel preparation (odds ratio 2.10; 95% CI 1.41–3.13). Their mean Boston Bowel Preparation Scale score was also 0.34 points lower than controls — a small absolute gap, but enough to push some preps from "good enough" into "please come back and do this again."
The mechanism is intuitive: GLP-1s slow gastric emptying and gut motility, which is a feature for blood sugar and appetite and a bug when you're trying to flush the colon clean overnight. The authors don't tell patients to stop their medication; they make the case that gastroenterologists need clearer pre-procedure guidance. If you're a parent who finally booked the screening colonoscopy you've been putting off, that's the conversation to have a week ahead of time — not the night before.
A signal is not a verdict. But it is a reason to ask better questions at the next appointment.
How worried should you actually be?
The honest answer, with the evidence at this strength, is: informed, not alarmed. FAERS analyses describe reporting patterns; they cannot tell you your personal risk, and they tend to over-represent dramatic or novel events. Meta-analyses of observational colonoscopy data are stronger but still observational. Neither study changes the underlying calculus that, for the right patient, GLP-1s deliver meaningful benefits for blood sugar, weight and increasingly cardiovascular outcomes.
What they do is round out the consent conversation. If you're newly on a GLP-1 and notice a persistent change in taste, smell, voice or hearing, that's worth flagging to your prescriber rather than chalking up to a bad cold or a bad week. If you have a colonoscopy scheduled, your gastroenterologist needs to know you're on one of these drugs — there may be an extended liquid diet or a modified prep plan that gets you through on the first try.
A week's notice before a procedure gives your clinician room to adjust prep — and saves you from a repeat.
- The ENT signal is real but preliminary. A FAERS review flagged taste, smell, voice and Bell's palsy reports across multiple GLP-1s — reporting data, not proof of cause.
- Bowel prep is measurably harder on a GLP-1. A meta-analysis of nearly 11,000 patients found roughly double the odds of inadequate prep.
- Tell your GI you're on a GLP-1 — early. A modified prep or longer clear-liquid window may be needed.
- Don't self-stop. Neither study recommends discontinuing the medication; both call for better clinician guidance.
- Track new symptoms simply. A note in your phone with dates beats trying to remember at the appointment.
- Talk to your prescriber. Persistent taste, smell, voice or hearing changes deserve a real conversation, not a Google rabbit hole.
None of this is a reason to panic-cancel a prescription that's working for you. It is a reason to treat these drugs the way you'd treat any powerful medication that's still revealing itself: with a good prescriber, honest symptom-tracking, and a low threshold for asking, "Is this normal?" The research is catching up to the prescriptions. Your job is just to stay in the conversation.
Sources
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists. — The Laryngoscope
- Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis. — The American journal of gastroenterology